{"id":"W2587280945","doi":"10.1093/annonc/mdw372.03","title":"First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Merck; Astellas Pharma US","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Internal medicine; Oncology; Clinical endpoint; Prostate-specific antigen; Cancer; Progressive disease; Urology; Androgen receptor; Clinical trial; Chemotherapy; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001115146,0.0003280881,0.0007092212,0.0002864845,0.0002518386,0.0009556168,0.000278176,0.0005223746,0.003735078],"category_scores_gemma":[0.003478128,0.0001641886,0.0004985969,0.0003793419,0.0003941653,0.000313054,0.000247218,0.001835724,0.0005666802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006497657,"about_ca_system_score_gemma":0.0008437354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008961714,"about_ca_topic_score_gemma":0.002679916,"domain_scores_codex":[0.9997051,0.00008285695,0.0000302542,0.0000388439,0.00009198066,0.00005089512],"domain_scores_gemma":[0.9970041,0.001795364,0.000346723,0.0001956113,0.0003574384,0.0003007927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04420862,0.002191059,0.05288411,0.004460008,0.001691896,0.002681602,0.0002371559,0.001174,0.07865572,0.001776985,0.03308365,0.7769552],"study_design_scores_gemma":[0.01013873,0.1234509,0.3945007,0.001106049,0.00431505,0.01547339,0.000317368,0.001615699,0.1216438,0.002925781,0.3243672,0.0001455302],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7630154,0.173037,0.002147956,0.01180055,0.00101687,0.0004793043,0.006798648,0.0003626068,0.04134176],"genre_scores_gemma":[0.973241,0.01705715,0.001054338,0.003253442,0.0004928785,0.00006592873,0.002358688,0.0000287965,0.002447811],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003735078,"threshold_uncertainty_score":0.01249504,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.209904179058089,"score_gpt":0.4719029272207172,"score_spread":0.2619987481626282,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}